[go: up one dir, main page]

TNSN99147A1 - Procede d'emulsification - Google Patents

Procede d'emulsification

Info

Publication number
TNSN99147A1
TNSN99147A1 TNTNSN99147A TNSN99147A TNSN99147A1 TN SN99147 A1 TNSN99147 A1 TN SN99147A1 TN TNSN99147 A TNTNSN99147 A TN TNSN99147A TN SN99147 A TNSN99147 A TN SN99147A TN SN99147 A1 TNSN99147 A1 TN SN99147A1
Authority
TN
Tunisia
Prior art keywords
fkbp
preparation
compounds
emulsification process
concerns
Prior art date
Application number
TNTNSN99147A
Other languages
English (en)
Inventor
Ian Kemp Mark
John Palmer Michael
Allen Sanner Mark
James Wythes Martin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN99147A1 publication Critical patent/TNSN99147A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

-L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE A, Y, R, X, R1, R2, R3 ET R4 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION, DES INTERMEDIAIRES UTILISES DANS CETTE PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEURS D'ENZYMES CONSISTANT EN ROTAMASES, EN PARTICULIER FKBP-12 ET FKBP-52, POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES.
TNTNSN99147A 1998-07-21 1999-07-20 Procede d'emulsification TNSN99147A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815880.1A GB9815880D0 (en) 1998-07-21 1998-07-21 Heterocycles

Publications (1)

Publication Number Publication Date
TNSN99147A1 true TNSN99147A1 (fr) 2005-11-10

Family

ID=10835920

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99147A TNSN99147A1 (fr) 1998-07-21 1999-07-20 Procede d'emulsification

Country Status (45)

Country Link
US (2) US6372736B1 (fr)
EP (1) EP1100797B1 (fr)
JP (2) JP3795329B2 (fr)
KR (2) KR100450008B1 (fr)
CN (3) CN1611499A (fr)
AP (1) AP2001002046A0 (fr)
AR (1) AR019427A1 (fr)
AT (1) ATE233261T1 (fr)
AU (1) AU765925B2 (fr)
BG (1) BG105254A (fr)
BR (1) BR9912330A (fr)
CA (1) CA2338214C (fr)
CO (1) CO5080782A1 (fr)
CR (1) CR6073A (fr)
DE (1) DE69905582T2 (fr)
DK (1) DK1100797T3 (fr)
DZ (1) DZ2851A1 (fr)
EA (1) EA003513B1 (fr)
EE (1) EE200100044A (fr)
ES (1) ES2191484T3 (fr)
GB (1) GB9815880D0 (fr)
GE (1) GEP20033028B (fr)
GT (1) GT199900115A (fr)
HK (1) HK1039779A1 (fr)
HN (1) HN1999000106A (fr)
HR (1) HRP20010052A2 (fr)
HU (1) HUP0103413A3 (fr)
ID (1) ID26991A (fr)
IL (1) IL140244A0 (fr)
IS (1) IS5790A (fr)
MA (1) MA24936A1 (fr)
MY (1) MY118222A (fr)
NO (1) NO20010322L (fr)
NZ (2) NZ508838A (fr)
OA (1) OA11585A (fr)
PA (1) PA8478501A1 (fr)
PE (1) PE20001037A1 (fr)
PL (1) PL345734A1 (fr)
SI (1) SI1100797T1 (fr)
SK (1) SK772001A3 (fr)
SV (1) SV1999000102A (fr)
TN (1) TNSN99147A1 (fr)
TR (1) TR200100135T2 (fr)
TW (1) TWI229672B (fr)
WO (1) WO2000005232A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
CZ20011546A3 (cs) 1998-11-03 2001-08-15 Basf Aktiengesellschaft Derivát substituovaného 2-fenylbenzimidazolu, způsob jeho přípravy a jeho použití
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE10124953A1 (de) * 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
JP4812758B2 (ja) * 2004-06-29 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｆｋｂｐ結合組成物及びその医薬上の使用
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006110683A1 (fr) * 2005-04-11 2006-10-19 Abbott Laboratories 1h-benzimidazole-4-carboxamides 2-substitues en tant qu'inhibiteurs de parp
JP5227796B2 (ja) * 2005-09-29 2013-07-03 アボット・ラボラトリーズ ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
US7462724B2 (en) * 2005-11-15 2008-12-09 Abbott Laboratories Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
HUE031972T2 (en) 2005-12-29 2017-08-28 Celtaxsys Inc Diamine derivatives as inhibitors of leukotriene a4 hydrolase
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
KR101426093B1 (ko) * 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
US20070259937A1 (en) * 2006-05-02 2007-11-08 Giranda Vincent L Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
US8338455B2 (en) 2006-12-20 2012-12-25 Amgen Inc. Compounds and methods of use
CL2008000666A1 (es) * 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
AU2008285289A1 (en) * 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010083199A1 (fr) * 2009-01-19 2010-07-22 Abbott Laboratories Inhibiteurs benzthiazole de la poly(adp-ribose)polymérase
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
EP2968265A4 (fr) 2013-03-14 2016-12-28 Celtaxsys Inc Inhibiteurs de la leucotriène a4 hydrolase
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
WO2015179414A1 (fr) * 2014-05-19 2015-11-26 Merial, Inc. Composés anthelmintiques
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
JPS6428245A (en) 1987-07-22 1989-01-30 Sumitomo Electric Industries Production of fluoride glass
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
AP2001002046A0 (en) 2001-03-31
CN1310718A (zh) 2001-08-29
GT199900115A (es) 2001-01-10
SV1999000102A (es) 2000-07-06
EA003513B1 (ru) 2003-06-26
GB9815880D0 (en) 1998-09-16
EE200100044A (et) 2002-06-17
EP1100797B1 (fr) 2003-02-26
ATE233261T1 (de) 2003-03-15
GEP20033028B (en) 2003-07-25
DE69905582T2 (de) 2003-09-04
NO20010322L (no) 2001-03-15
JP2002521382A (ja) 2002-07-16
AU4285899A (en) 2000-02-14
MY118222A (en) 2004-09-30
IL140244A0 (en) 2002-02-10
ID26991A (id) 2001-02-22
NO20010322D0 (no) 2001-01-19
JP2004002374A (ja) 2004-01-08
AR019427A1 (es) 2002-02-20
ES2191484T3 (es) 2003-09-01
CA2338214C (fr) 2006-08-01
BG105254A (en) 2001-10-31
HK1039779A1 (zh) 2002-05-10
KR20040062640A (ko) 2004-07-07
CR6073A (es) 2004-04-29
OA11585A (en) 2004-07-26
WO2000005232A1 (fr) 2000-02-03
KR20010071013A (ko) 2001-07-28
CA2338214A1 (fr) 2000-02-03
JP3795329B2 (ja) 2006-07-12
HUP0103413A2 (hu) 2002-05-29
PE20001037A1 (es) 2000-10-11
PL345734A1 (en) 2002-01-02
CN1511837A (zh) 2004-07-14
KR100468185B1 (ko) 2005-01-26
SI1100797T1 (en) 2003-06-30
HUP0103413A3 (en) 2002-10-28
HRP20010052A2 (en) 2001-12-31
DZ2851A1 (fr) 2004-02-04
MA24936A1 (fr) 2000-04-01
CO5080782A1 (es) 2001-09-25
AU765925B2 (en) 2003-10-02
IS5790A (is) 2000-12-22
TR200100135T2 (tr) 2001-06-21
EA200100052A1 (ru) 2001-06-25
NZ508838A (en) 2002-12-20
NZ522270A (en) 2004-03-26
CN1611499A (zh) 2005-05-04
TWI229672B (en) 2005-03-21
KR100450008B1 (ko) 2004-09-24
US6372736B1 (en) 2002-04-16
EP1100797A1 (fr) 2001-05-23
HN1999000106A (es) 1999-11-11
BR9912330A (pt) 2001-04-17
CN1174978C (zh) 2004-11-10
US6562964B1 (en) 2003-05-13
DE69905582D1 (de) 2003-04-03
DK1100797T3 (da) 2003-04-22
PA8478501A1 (es) 2000-05-24
SK772001A3 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
TNSN99147A1 (fr) Procede d'emulsification
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98036A1 (fr) Derives d'acide hexanoique nouveaux
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN98066A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97148A1 (fr) Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant